Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
PRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.01 - $91.83
Previous CloseN/A
Volume51.58K
Average Volume (3M)488.92K
Market Cap
$719.42M
Enterprise Value$731.25M
Total Cash (Recent Filing)-$17.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 07, 2025EPS Estimate
-3.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.27
Shares Outstanding18,637,777
10 Day Avg. Volume712,231
30 Day Avg. Volume488,916
Standard Deviation0.33
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)448.79
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit298.83
Enterprise Value/Ebitda-4.47
Forecast
1Y Price Target
$119.50Price Target Upside256.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Epilepsy PortfolioAnalyst maintains a BUY rating on FOS (vormatrigine) and DEE (relutrigine) which remain on track to deliver data throughout 2025.
Financial StabilityCash of $469.5M provides financial stability and runway to 2028.
Bears Say
Study FutilityThe IDMC recommended stopping Study 1 for futility, impacting the valuation of PRAX.
---
Ownership Overview
10.85% Insiders
19.33% Mutual Funds
3.00% Other Institutional Investors
53.17% Public Companies and Individual Investors
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $33.01 and its highest was $91.83 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $719.42M.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is May 07, 2025 which is in 64 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Feb 28, 2025. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.847 by -$0.093.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.2.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 18,637,777 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.847. Following the earnings report the stock price went down -40.643%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
---
Praxis Precision Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.50 (256.18% Upside)
$119.50 (256.18% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 175.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.11%
12-Months-Change
Fundamentals
Return on Equity
-70.98%
Trailing 12-Months
Asset Growth
449.31%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Praxis's pipeline, particularly with promising results in their epilepsy programs and a solid financial position. However, there were concerns about delays in clinical trial timelines and challenges in managing placebo effects, which could impact future outcomes.Read More>---
PRAX Stock 12 Month Forecast
Average Price Target
$119.50
▲(256.18% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Cytokinetics
―
SAGE Therapeutics
―
Viking Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
11/27 ratings generated profit
1 Year Average Return
+59.80%
reiterated a buy rating 2 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of +59.80% per trade.
---